Bayer Data at ASCO 2019 Highlights Commitment to Evolving the Cancer Treatment Paradigm

Monday, May 13, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

- Data include new analyses on VitrakviŪ (larotrectinib), with two oral presentations in patients with solid tumors that harbor an NTRK gene fusion: one on expanded data in pediatric patients and the other on patients with brain metastases or primary central nervous system tumors



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store